Business Parks & Science Centres

 
 
 

Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 600x60px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements from Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 5658 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 38 39 40 ... 55 56 57  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Jacobs Univ–EU (govt): grant, 201202–201601 FP7 grant for Jacobs Univ as project partner + co-ordinator of €9m Micro B3 project 2012-02-01
Max Planck–EU (govt): grant, 201202–201601 FP7 grant for MPI for Marine Microbiology as partner of €9m Micro B3 project 2012-02-01
Micro B3 project–EU (govt): grant, 201202–201601 FP7 grant €9m to create integrative database on marine microorganisms 2012-02-01
Micro B3 project–Jacobs Univ: marine microorganism database, 201202–201601 collab Jacobs Univ is partner + co-ordinator of Micro B3 FP7 project 2012-02-01
Micro B3 project–Max Planck: marine microorganism database, 201202–201601 collab MPI for Marine Microbiology is project partner 2012-02-01
Micro B3 project–Ribocon: marine microorganism database, 201202–201601 collab Ribocon GmbH is project partner 2012-02-01
Ribocon–EU (govt): grant, 201202–201601 FP7 grant for Ribocon GmbH as partner of €9m Micro B3 project 2012-02-01
B Braun–CeGaT: personalised medicine, 201201– collab strategic partnership to expand + internationalise CeGaT’s business 2012-01-31
CeGaT–B Braun: investment, 201201 acquisition of 20% share as part of strategic partnership to expand + internationalise CeGaT’s business 2012-01-31
Implandata–High-Tech Gründerfonds: investment, 201201 financing round Series A first closing totalling €1.4m incl investor HTGF 2012-01-30
Implandata–SEVERAL: investment, 201201 financing round Series A first closing €1.4m HTGF + Hannover Beteiligungsfonds + private investors 2012-01-30
Roche–Curis: vismodegib, 201201 collab existent developm of Erivedge which has been discovered by Genentech 2012-01-30
Roche–Hamilton: lab automation technology, 201201 collab existent product integration for DNA sample enrichment solution 2012-01-30
Bruker Corp–Siscapa: SISCAPA assay technology, 201201 collab developm for MALDI-TOF MS for proteomic marker validation + clin research 2012-01-27
Analytik Jena–Thuringia (govt): investment, 201201–201202 capital increase €4.9m 470k shares €10.48/share TIB increases bm-t share 10.41 to 17.79% 2012-01-26
Hecus X-Ray Systems–Bruker Corp: investment, 201201 acquisition of assets €na by Bruker AXS GmbH from founder + owner Peter Laggner 2012-01-26
Micromet–Amgen: investment, 201201–201203 acquisition $1.16b cash tender offer $11/share 2012-01-26
Illumina–Roche: investment, 201201–201204 unsolicited cash tender offer $5.7b $44.5/share raised to $51/share NOT REALISED 2012-01-25
Spectrum Pharmaceuticals–Bayer: ibritumomab tiuxetan, 201201– acqu ww marketing rights w addit license for Zevalin outside US from Bayer HealthCare 2012-01-25
Immatics–Huntsworth: public relations, 201201 service existent by Citigate Dewe Rogerson 2012-01-24
Labcyte–Qiagen: siRNA libraries, 201201– collab product integration Qiagen siRNA libraries available in Labcyte Echo qualified microplates 2012-01-24
Sartorius–Refine Technology: cell culture technology, 201201– collab product integration of ATF System with BIOSTAT bioreactors 2012-01-23
Oroxcell–Thermo Fisher: mass spectrometer, 201201 supply existent TSQ Quantum Ultra triple quad LC-MS/MS listed as equipment on web site 2012-01-20
Oroxcell–Waters: mass spectrometer, 201201 supply existent Quattro Micro triple quad LC-UV-MS/MS-Radiodetector listed as equipment on web site 2012-01-20
Oroxcell–Waters: mass spectrometer, 201201 supply existent ZMD single quad LC-UV-MS listed as equipment on web site 2012-01-20
Roche–Technoclone: coagulation diagnostics, 201201– collab strategic alliance 2012-01-19
Bruker Corp–SEVERAL: credit, 201201–201701 Senior Notes $20m 3.16% Series 2012A Tranche A due 18 Jan 2017 2012-01-18
Bruker Corp–SEVERAL: credit, 201201–201901 Senior Notes $15m 3.74% Series 2012A Tranche B due 18 Jan 2019 2012-01-18
Bruker Corp–SEVERAL: credit, 201201–202201 Senior Notes $105m 4.31% Series 2012A Tranche C due 18 Jan 2022 2012-01-18
Bruker Corp–SEVERAL: credit, 201201–202401 Senior Notes $100m 4.46% Series 2012A Tranche D due 18 Jan 2024 2012-01-18
Nova Capital–Eppendorf: thermal cycler, 201201– license covering gradient technology for thermal cyclers to Bibby Scientifc Ltd 2012-01-18
Polyplus-transfection–Andrew Lloyd Associates: public relations, 201201 service existent by ALA 2012-01-18
Sartorius–G-Con Manufacturing: cleanroom technology, 201201– collab ww product integration + offering of biopharma manufacturing solutions SSB 2012-01-18
Bayer–Roche: molecular companion diagnostics, 201201– collab developm of IHC companion diagnostic for new Bayer cancer antibody-drug conjugate Ventana 2012-01-17
BBG/Braun Group–Enzymicals: fine chemicals, 201201– collab biocatalytic processes integration of know-how of Herbrand PharmaChemicals + Enzymicals 2012-01-17
Waters–Tecan: liquid handling technology, 201201– supply €na OEM Freedom EVO platform for Waters clinical lab assays with ACQUITY TQD LS/MS/MS 2012-01-17
Bayer–Nomad Bioscience: investment, 201201 acquisition €na all assets + obligations of Icon Genetics GmbH from Bayer Innovation by Nomad Bioscience 2012-01-12
BioMedTec Wissenschaftscampus–Univ Lübeck: medical technology, 201201– Koop Univ Lübeck is founding partner 2012-01-12
Univ Lübeck–Euroimmun: medical technology, 201201– collab Euroimmun AG is founding partner of BioMedTec Wissenschaftscampus Lübeck 2012-01-12
Univ Lübeck–FH Lübeck: medical technology, 201201– collab FH Lübeck is founding partner of BioMedTec Wissenschaftscampus Lübeck 2012-01-12
Univ Lübeck–Fraunhofer: medical technology, 201201– collab Fraunhofer EMB is founding partner of BioMedTec Wissenschaftscampus 2012-01-12
Univ Lübeck–Fraunhofer: medical technology, 201201– collab Fraunhofer MEVIS Bildregistrierung is founding partner of BioMedTec Wissenschaftscampus 2012-01-12
Univ Lübeck–Leibniz-Gemeinschaft: medical technology, 201201– collab Research Center Borstel is founding partner of BioMedTec Wissenschaftscampus 2012-01-12
Organobalance–Comago: public relations, 201201 supply service existent 2012-01-11
Sanofi–Organobalance: yeast technology, 201201– license excl for vaccine production of modified S. cerevisiae strain to Sanofi Pasteur 2012-01-11
Qiagen–Insight Genetics: genomic biomarker, 201201– license excl ww for genetic test inc ALK marker for PDx in lung cancer 2012-01-10
Qiagen–Personal Genome Diagnostics: genomic biomarker, 201201– license excl ww to Ipsogen for IDH1/IDH2 marker for PDx in brain + other cancers 2012-01-10
Telormedix–Avaris: investment, 201201 financing round totalling CHF7.5m from existing investors Aravis Venture + ProQuest Investments 2012-01-10
Telormedix–ProQuest Investments: investment, 201201 financing round totalling CHF7.5m from existing investors Aravis Venture + ProQuest 2012-01-10
Telormedix–SEVERAL: investment, 201201 financing round CHF7.5m from existing investors Aravis Venture + ProQuest Investments 2012-01-10
Dualsystems Biotech–Nikem Research: drug discovery services, 201201– collab strategic alliance combined offering of profiling + discovery services 2012-01-09
JnJ–Proteros: drug discovery services, 201201– supply lead discovery services expanded to global long-term agreem w Janssen R&D 2012-01-09
Qiagen–Max Planck: molecular diagnostics, 201201– collab developm test for active TB risk w latent infection w MPI for Infection Biology 2012-01-09
Wilex–SEVERAL: investment, 201201–201202 capital increase €9.93m with 3.2m new authorised shares €3.1/share 2012-01-09
AMP-Therapeutics–Boehringer: investment, 201201 financing round Series A from Boehringer Ingelheim Venture Fund + Novartis Venture Funds 2012-01-05
AMP-Therapeutics–Novartis: investment, 201201 financing round Series A from Boehringer Ingelheim Venture Fund + Novartis Venture Funds 2012-01-05
AMP-Therapeutics–SEVERAL: investment, 201201 financing round Series A from Boehringer Ingelheim Venture Fund + Novartis Venture Funds 2012-01-05
Apogenix–SEVERAL: investment, 201201 financing round €7.5m lead investor Dievini Hopp Biotech Holding 2012-01-05
Boehringer–Forma Therapeutics: cancer drugs, 201201– collab r+d $65m upfront + funding + $750m milestones small-molecule cancer drugs 2012-01-05
Probiodrug–SEVERAL: investment, 201201 financing round €15m from existing investors + new investor Wellington Management 2012-01-04
Apogenix–Germany (govt): grant, 201201 BMBF grant €2.3m for developm of APG101 for myelodysplastic syndromes 2012-01-03
Bayer–Cellectis: Meganuclease technology, 201201– collab extension €na use to develop agricultural seeds Bayer CropScience + Cellectis Plant Sciences 2012-01-03
Biognosys–ETH Zürich: HRM-MS technology, 201201 collab development Aebersold group 2012-01-03
Biognosys–Switzerland (govt): grant, 201201 grant CHF1.5m to Biognosys + Aebersold Group at ETH Zurich for developm of HRM-MS technology 2012-01-03
Renmatix–BASF: investment, 201201 financing round totalling $50m incl $30m from lead investor BASF Biorenewable Beteiligungs GmbH & Co KG 2012-01-03
Renmatix–SEVERAL: investment, 201201 financing round $50m lead investor BASF Biorenewable Beteiligungs GmbH & Co KG 2012-01-03
DASGIP–Eppendorf: investment, 201201 acquisition €na 2012-01-02
Galecto Biotech–Merck (DE): investment, 201201 seed financing round co-led by Merck Serono Ventures + Novo Seeds 2012-01-02
Galecto Biotech–Novo Group: investment, 201201 seed financing round co-led by Merck Serono Ventures + Novo Seeds 2012-01-02
Galecto Biotech–SEVERAL: investment, 201201 seed financing round co-led by Merck Serono Ventures + Novo Seeds 2012-01-02
Univ Bochum–Waters: mass spectrometer, 201201 supply Synapt G2S HDMS €800k to Bandow Group at Dept of Biology & Biotechnology financed by State of NRW 2012-01-02
ADC Therapeutics–Celtic Therapeutics: investment, 2012 acquisition of majority share in newly founded ADC Therapeutics 2012-01-01
Analytik Jena–Endress+Hauser: investment, 2012 initial investment of Endress+Hauser in Analytik Jena AG 2012-01-01
AppliChem–Illinois Tool Works: investment, 201201 acquisition of AppliChem by ITW 2012-01-01
Bayer–X-Chem: small-molecule drug discovery, 2012– collab research using DEX technology 2012-01-01
BioEconomy Cluster–Germany (govt): grant, 201201– BMBF Spitzencluster grant up to €40m for 5 years 2012-01-01
Bruker Corp–Univ Geneva: magnet technology, 2012– collab development of superconducting coils for NMR + MRI magnets 2012-01-01
CI3 Cluster–Germany (govt): grant, 201201– BMBF Spitzencluster grant up to €40m for 5 years 2012-01-01
Debiopharm–Dr. Reddy’s: Debio 0617B, 2012– license ww excl for devlopm + commercialisation from Aurigene Discovery Technologies 2012-01-01
Dima–Mérieux: investment, 2012 DIVESTMENT of Dima GmbH by bioMérieux 2012-01-01
Eyevensys–SEVERAL: investment, 201201 1st financing round €1.6m Innobio + Inserm Transfert + CapDecisif Management 2012-01-01
Gilupi–Viroad: investment, 2012 investment in connnection w strategic partnership making Viroad largest shareholder of Gilupi 2012-01-01
IMMOMEC project–EU (govt): grant, 201201–201512 FP7 grant €7.4m 2012-01-01
JnJ–Phenex: RORgt inhibitors, 2012– collab r+d up to $135m for chronic inflammatory + autoimmune disease w Janssen Biotech 2012-01-01
KBI BioPharma–Selexis: cell line development, 2012– supply service use of cell lines created using SUREtechnology platform by KBI 2012-01-01
Novartis–PeptiDream: drug discovery, 2012– collab strategic alliance using PDPS technology for peptide-based drug discovery 2012-01-01
OPTATIO project–EU (govt): grant, 201201– FP7 grant for project co-ordinated by CEMIT 2012-01-01
Qtis/e–Xeltis: investment, 2012 merger of Qtis/e with Xeltis 2012-01-01
Selexys Pharmaceuticals–Novartis: investment, 201611 acquisition by Novartis for up to $665m upfront + acquisition + milestone payments 2012-01-01
Sigma-Aldrich–Atlas Antibodies: research antibodies, 201201 distribution existent ww under brand name Prestige Antibodies by Sigma-Aldrich 2012-01-01
TIMER project–EU (govt): grant, 201201–201512 EU funding €3m out of total project cost of €4m 2012-01-01
TIMER project–Merck (DE): antinflammatory drug research, 201201–201512 Merck Sereno SA is partner in EU 3y EU project 2012-01-01
TIMER project–Telormedix: antinflammatory drug research, 201201–201512 Telormedix is partner in EU 3y EU project 2012-01-01
Univ Cambridge–Danaher: mass spectrometer, 2012 supply AB SCIEX TripleTOF 5600+ system with SWATH Acquisition to Ralser Lab 2012-01-01
Valdea Biosciences–Integra Holding: investment, 2012 acquisition by Integra Biosciences 2012-01-01
Valdea Biosciences–Integra Holding: laboratory equipment, 2012 distribution existent in France by Valdea Biosciences SAS 2012-01-01
Viroad–Gilupi: diagnostic device, 2012 collab strategic partnership incl investment making Viroad largest shareholder of Gilupi 2012-01-01
Xiril–Sias: investment, 2012 acquisition of Xiril AG by Sias AG 2012-01-01
Apeptico–Austria (govt): grant, 201112 grant €1.4m from FFG 2011-12-31
Coral BioNet–Nanohale: investment, 20112 acquisition €na all assets of Formycon business unit of Scil Technology GmbH 2011-12-31
next pagenext page 1 2 3 ... 38 39 40 ... 55 56 57  next pagenext page



Advertisement

Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

» top